Follow The Filings

HBIO Harvard Bioscience

Harvard Bioscience earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by HBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All HBIO insider trades
  • $202K bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Mark T Frost CFO
    Buy
    $25K 5,000 shares at $5.00 +40% to stake
    Traded Mar 16 Filed Apr 1
  2. Stephen J Denelsky Director
    Buy
    $49K 10,000 shares at $4.87 +91% to stake
    Traded Mar 17 Filed Mar 18
  3. William Snider Director
    Buy
    $104K 21,000 shares at $4.93 +191% to stake
    Traded Mar 16–17 Filed Mar 18
  4. John D Duke CEO
    Buy
    $25K 5,000 shares at $5.01 +5% to stake
    Traded Mar 16 Filed Mar 17

Also filed in the last 12 months, not counted as buying or selling: 8 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
8-K 2.02,9.01
8-K 7.01,9.01
10-Q FORM 10-Q
8-K 5.02,5.07,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
8-K 7.01,9.01
10-Q FORM 10-Q
DEF 14A FORM DEF 14A
DEFA14A FORM DEFA14A
SCHEDULE 13D —
8-K 7.01,9.01
10-K FORM 10-K
8-K 2.02,9.01
8-K 5.02,9.01
8-K 5.07,7.01,8.01,9.01
SCHEDULE 13G/A —
8-K 2.02,9.01
424B3 FORM 424B3
DEF 14A
8-K 2.05,7.01,9.01
8-K 5.03,9.01
8-K 7.01,9.01
8-K 1.01,1.02,2.03,5.02,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.